Shares of Novavax Inc. have dropped significantly by 26% following recent statements made by U.S. Secretary of Health and Human Services Robert F. Kennedy Jr., who expressed doubts about the efficacy of the company’s COVID-19 vaccine. This development has caught the attention of both investors and health experts alike.